ClinicalTrials.gg
TerminatedNCT05729425Updated Aug 18, 2023

Evaluating the Accuracy of Microvessel Ultrasound Imaging for Detecting Extent of Disease in Patients With Angiosarcoma of the Skin

An observational study in Skin Angiosarcoma, sponsored by Mayo Clinic. Terminated at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Mayo Clinic · Observational

Why this study was terminated
Unable to recruit participants due to rare disease
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1
Ages
21 Years and older
Sex
All
01

Study summary

This study evaluates the accuracy of a new ultrasound technology called microvessel imaging for detecting the extent of disease among patients with angiosarcoma of the skin. Microvessel ultrasound imaging uses high frequency waves to visualize vessels in the skin that are not easily seen using other imaging tests.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the accuracy of depicting extent of disease of cutaneous angiosarcoma before and after neoadjuvant treatment compared to clinical photographs, magnetic resonance imaging (MR) or positron emission tomography (PET)/computed tomography (CT) imaging and surgical pathology both on skin biopsies and surgical excision.

OUTLINE:

Patients undergo microvessel ultrasound imaging on study.

02

Conditions studied

  • Skin Angiosarcoma

Browse trials for

03

In context

Hemangiosarcoma

99 studies on the registry are indexed under Hemangiosarcoma; 16 are open to participants now.

Browse Hemangiosarcoma studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over the age of 21 with new diagnosis of cutaneous angiosarcoma of the breast or scalp.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with cutaneous angiosarcoma of the breast or scalp and scheduled for trimodality therapy
  • Twenty one years of age or older

Exclusion criteria

Exclusion Criteria:

  • Unwilling to consent to microvessel ultrasound imaging
  • Younger than 21 years of age
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1 participant (actual)

Groups and cohorts

  • Observational (microvessel ultrasound imaging)

    Patients undergo microvessel ultrasound imaging on study.

    Device: Ultrasound Microvessel Imaging

Interventions

  • DeviceUltrasound Microvessel Imaging

    Undergo microvessel ultrasound imaging

    Also known as: 3D Ultrasound Microvessel Imaging, UMI

06

What researchers measure

Primary outcomes

  1. Accuracy of microvessel ultrasound imaging

    Accuracy with respect to gold standard quantitative measures of disease extent and imaging-based measurements will be evaluated using Lin's concordance correlation coefficient along with 95% confidence intervals (CI's). These will be performed separately pre- and post-treatment. Pearson correlations and 95% CI's between imaging modality measurements will also be estimated to help guide future comparative analyses. Bland-Altman plots will also be generated to visualize agreement.

    Time frame: Through to study completion up to one year

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Aug 2023, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 15, 2023
StartActual
Oct 31, 2022
Primary completionActual
Aug 15, 2023
CompletionActual
Aug 15, 2023
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05729425
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
Oct 31, 2022
Primary completion
Aug 15, 2023
Completion
Aug 15, 2023
Last update
Aug 18, 2023

Study contacts

Tiffany M Sae-Kho
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion